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Introduction
Cerebral Cavernous Malformations (CCM) are common central nervous system (CNS) vascular anomalies that occur either sporadically or heritably and affect ~1/200 humans. 1 Mutations of three genes KRIT1 (CCM1), CCM2, or PDCD10 (CCM3) are associated with development of CCM, cerebral venous capillary dysplasias with clusters of endothelium filled with blood and prone to hemorrhage. 2, 3 The KRIT1 +/-genotype is the most common cause of the familial form of CCM, whereas the PDCD10 +/-genotype often results in a more severe clinical manifestation of the disease. 4, 5 Unlike sporadic CCM, where a single lesion is typically observed, familial CCM are characterized by multiple vascular lesions believed to be due to random inactivation of the normal allele. 1, 4, 6 Moreover, a combination of chronic bleeding and episodes of acute hemorrhagic stroke, associated with CCM, cause focal neurological deficits, headaches, epileptic seizures, and occasionally death. 7 In addition, patients with PDCD10 mutations are more likely to present significant CCM hemorrhages earlier in life. 4 Although the annual symptomatic hemorrhage rate varies largely among different studies from 0.25 to 22.9% per patient-year, 2, 8 it is thought that all CCM harbor occult bleeding. 7, 8 Natural history studies and MRI analysis have identified prior CCM bleeding within a year as a predictor of repeated hemorrhage and subsequent clinical sequelae.7,9,10 However, the detailed molecular mechanisms underlying the pathogenesis of CNS hemorrhage in CCM remains elusive.
Recently, we performed genome-wide transcriptome analysis of the acute effects of inactivation of Krit1 in murine brain endothelial cells (BMEC) and found increased levels of Thbd mRNA, which encodes the natural anticoagulant receptor, thrombomodulin (TM). 11 Although TM levels are notably low in normal young brain endothelium, it plays a role in the thromboresistant properties of the brain. 12, 13 TM binds thrombin and, while bound, thrombin fails to convert fibrinogen into insoluble fibrin, and instead catalyzes formation of activated protein C (APC). APC generation is enhanced by the presence of the endothelial cell protein receptor (EPCR), 13, 14 the mRNA of which is also increased with loss of Krit1 in BMECs.
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Because APC is a potent natural anticoagulant, high levels of TM have been associated with a bleeding disorder 15, 16 and used as a biomarker of endothelial cell dysfunction, 17 we hypothesized that increased TM and EPCR could create a local bleeding diathesis in CCM.
Here we show that TM is upregulated in CCM lesions, and in the plasma of individuals with the sporadic or familial form of the disease. In two acute models of CCM, we report marked increases in brain endothelial TM and EPCR following genetic inactivation of Krit1 or Pdcd10. 
Results

Increased TM expression in CCM lesions
We recently performed genome-wide transcriptome analysis of the effects of acute inactivation of Krit1 in murine brain endothelial cells (BMEC) and observed increased Thbd mRNA that encodes a major anticoagulant endothelial receptor, TM. 11 TM expression is modest in normal brain microvasculature relative to systemic blood vessels, suggesting that the brain is a hemostatically "privileged" environment to avert hemorrhage. 13, 22, 23 To examine whether TM expression is increased in human CCM, we stained lesions obtained at surgery. TM staining was increased in the endothelium of human CCM lesions in comparison to lesion-free brain tissue from a CCM patient or non-neurological disease control ( Figure 1A ).
Furthermore, increased expression of TM in CCM endothelial cells was confirmed by a ~ 2.9 fold increase in THBD mRNA in CCM lesion endothelial cells isolated by laser capture microdissection ( Figure 1B ).
We next examined venous plasma levels of soluble TM in familial and sporadic forms of CCM. Significantly increased soluble TM was detected in patients with familial CCM due to mutations in KRIT1(CCM1) or PDCD10(CCM3) (mean=3.57 ng/ml ± 0.64) compared to healthy subjects (mean=2.78 ng/ml ± 0.11). There was also a significantly increased soluble TM in sporadic CCM patients (mean=3.06 ng/ml ± 0.03) ( Figure 1C ). Thus CCM lesions arising from loss of function of either KRIT1 (CCM1) or PDCD10 (CCM3) led to an increase in TM protein and mRNA levels in CCM lesions and an increase of TM in the plasma. BMECs, respectively ( Figure 3C ).
Loss of brain endothelial
KLF2 and KLF4 regulate expression of endothelial TM in CCM
Transcription factors KLF2 and KLF4 are regulators of endothelial anticoagulant gene expression. [24] [25] [26] [27] We confirmed that the changes in brain endothelial TM, at the protein and mRNA levels, were associated with a large increase in transcription factors KLF2 and KLF4 in both Krit1 ECKO and Pdcd10 ECKO BMECs ( Figure 3D ,E).
Therefore, to test whether a rise in KLF2 and KLF4 are inducers of TM during CCM, we used lentivirus-mediated transduction to ectopically express KLF2 and KLF4 in human endothelial cells ( Figure 4A ) at levels that we previously showed to suppress a t arget gene, Thbs1. 11 Overexpression of KLF2 and KLF4 led to significant increase in TM mRNA levels when compared to control GFP-infected cells ( Figure 4B ). We also observed that ectopic expression of KLF2 or KLF4 resulted in ~4.2 fold or ~5.8 fold increases in TM protein, respectively as determined by Western blot analysis ( Figure 4C ). Flow cytometry analysis showed that membrane bound endothelial TM was ~4 fold-increased in KLF4
overexpressing cells when compared to control infected cells ( Figure 4D ,E).
Moreover, we observed that reducing the expression of KLF2 and KLF4 ( Figure 4F ,G) prevented increased TM expression in KRIT1-depleted human brain endothelial cells ( Figure 4H ). Together these observations suggest that the rise in KLF2 and KLF4 lead to increased brain endothelial TM in CCMs. Figure 5E ,F). There was no increase in PECAM1 abundance as assessed by Western blot, confirming that the increased TM was not due to increased density of blood vessels (Data not shown). Moreover, we observed increase in TM levels in heart but not in lung or intestine tissue from Pdcd10 ECKO mice ( Figure 5F ). We also noted that expression of both KLF2 and KLF4 was markedly increased in Pdcd10 ECKO hindbrain tissue ( Figure 5G ) corroborating previous findings. 28 The Pdcd10 Figure 1) 
Brain endothelial TM increase is accompanied by hemorrhage in
EPCR expression in the brain is upregulated in CCM but is not regulated by
KLF2 or KLF4
EPCR, an endothelial transmembrane protein that presents protein C to the thrombin-TM complex 14 is expressed in the brain vasculature and plays a crucial role in the vascular anticoagulant pathway 29, 30 by facilitating protein C activation. 31 We next investigated whether EPCR levels were also altered in CCMs. PROCR ( Figure 7B ) as signaled by a ~2 fold reduction in extractable hemoglobin in Pdcd10 ECKO mice ( Figure 7B ). These data suggest that CCMs caused by mutations of KRIT1 or PDCD10 lead to the formation of an anticoagulant vascular domain due to increased expression of TM and EPCR drivenin part by transcription factors KLF2 and KLF4 thereby contributing to increased hemorrhage ( Figure 7C ). Sangwung et al 48 show that endothelial cell loss of KLF2 and KLF4 results in substantial loss of TM and we report here that overexpression of these transcription factors can drive TM expression, as would be predicted from previous studies. [24] [25] [26] There is now compelling evidence that elevation of KLF2 and KLF4 make important contributions to the pathogenesis of CCM. 11, 28, 42, 49 Endothelialspecific deletion of KLF2 and KLF4 in adults leads to lethality 48 indicating that inhibition of these transcription factors is unlikely to be a suitable therapeutic strategy. Here we add the upregulation of TM to the growing list 11 of KLF2 and KLF4 targets that can contribute to the pathogenesis of CCM disease and might serve as therapeutic targets. In contrast, we could not ascribe the rise in EPCR expression to KLF2 and KLF4. In particular, depleting KRIT1 increased EPCR and TM expression in cultured endothelial cells whereas over expression of KLF2 and KLF4 only increased TM. Thus, the cell autonomous increase in EPCR does not appear to be a consequence of increased expression of KLF2 and KLF4 or of TM.
Discussion
The links between loss of CCM genes and increased EPCR expression could be a fruitful area for future work. vulnerability that follows such bleeds will be an important consideration for this. 7, 8 Another consideration is that the high level of APC in CCM lesions could diminish morbidity by means of its cytoprotective effects that include protection of vascular and blood-brain-barrier integrity. 
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